These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24727160)

  • 1. The effects of once-weekly teriparatide on hip geometry assessed by hip structural analysis in postmenopausal osteoporotic women with high fracture risk.
    Sone T; Ito M; Fukunaga M; Tomomitsu T; Sugimoto T; Shiraki M; Yoshimura T; Nakamura T
    Bone; 2014 Jul; 64():75-81. PubMed ID: 24727160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women.
    Uusi-Rasi K; Semanick LM; Zanchetta JR; Bogado CE; Eriksen EF; Sato M; Beck TJ
    Bone; 2005 Jun; 36(6):948-58. PubMed ID: 15878318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
    Sugimoto T; Shiraki M; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Kuroda T; Nakamura T
    Curr Med Res Opin; 2013 Mar; 29(3):195-203. PubMed ID: 23259702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of bazedoxifene on bone structural strength evaluated by hip structure analysis.
    Beck TJ; Fuerst T; Gaither KW; Sutradhar S; Levine AB; Hines T; Yu CR; Williams R; Mirkin S; Chines AA
    Bone; 2015 Aug; 77():115-9. PubMed ID: 25917574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial.
    Uusi-Rasi K; Beck TJ; Semanick LM; Daphtary MM; Crans GG; Desaiah D; Harper KD
    Osteoporos Int; 2006; 17(4):575-86. PubMed ID: 16392026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of once-weekly teriparatide on hip structure and biomechanical properties assessed by CT.
    Ito M; Oishi R; Fukunaga M; Sone T; Sugimoto T; Shiraki M; Nishizawa Y; Nakamura T
    Osteoporos Int; 2014 Mar; 25(3):1163-72. PubMed ID: 24345886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
    Prince R; Sipos A; Hossain A; Syversen U; Ish-Shalom S; Marcinowska E; Halse J; Lindsay R; Dalsky GP; Mitlak BH
    J Bone Miner Res; 2005 Sep; 20(9):1507-13. PubMed ID: 16059622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial.
    Greenspan SL; Beck TJ; Resnick NM; Bhattacharya R; Parker RA
    J Bone Miner Res; 2005 Sep; 20(9):1525-32. PubMed ID: 16059624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Once-weekly teriparatide treatment on osteoporosis].
    Nakano T
    Clin Calcium; 2014 Jan; 24(1):100-5. PubMed ID: 24369286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hip cortical thickness assessment in postmenopausal women with osteoporosis and strontium ranelate effect on hip geometry.
    Briot K; Benhamou CL; Roux C
    J Clin Densitom; 2012; 15(2):176-85. PubMed ID: 22321661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis.
    Krege JH; Wan X
    Bone; 2012 Jan; 50(1):161-4. PubMed ID: 22036910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
    Nakamura T; Sugimoto T; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Yoshikawa H; Nishizawa Y; Fujita T; Shiraki M
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3097-106. PubMed ID: 22723322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials.
    Han SL; Wan SL
    Int J Clin Pract; 2012 Feb; 66(2):199-209. PubMed ID: 22257045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in bone mineral density, bone turnover markers, and vertebral fracture risk reduction with once weekly teriparatide.
    Tanaka S; Kuroda T; Sugimoto T; Nakamura T; Shiraki M
    Curr Med Res Opin; 2014 May; 30(5):931-6. PubMed ID: 24392946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Femoral strength in osteoporotic women treated with teriparatide or alendronate.
    Keaveny TM; McClung MR; Wan X; Kopperdahl DL; Mitlak BH; Krohn K
    Bone; 2012 Jan; 50(1):165-70. PubMed ID: 22015818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate.
    Beck TJ; Lewiecki EM; Miller PD; Felsenberg D; Liu Y; Ding B; Libanati C
    J Clin Densitom; 2008; 11(3):351-9. PubMed ID: 18495508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study.
    Borggrefe J; Graeff C; Nickelsen TN; Marin F; Glüer CC
    J Bone Miner Res; 2010 Mar; 25(3):472-81. PubMed ID: 19778182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.